Impact of Insulin Degludec in Type 2 Diabetes: Real-World Data on Effectiveness and Safety

[1] Garber AJ(2012)Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN basal-bolus type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial Lancet 21 1498-1507

[2] King AB(2012)Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long) Diabetes Care 35 2464-2471

[3] Del Prato S(2013)Low volume insulin degludec 200U/ml once-daily improves glycemic control similar to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN™ LOW VOLUME trial Diabetes Care 36 2536-2542

[4] Zinman B(2013)The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel group, treat-to-target trial in individuals with type 2 diabetes Diabetes Care 36 858-864

[5] Philis-Tsimikas A(2013)Insulin degludec compared with insulin glargine in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, Pan-Asian, treat-to-target trial J Diabetes Investig 4 605-612

[6] Cariou B(2014)Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes Diabetes Obes Metab 14 859-864

[7] Gough S(2012)Ultra-long acting insulin degludec has a flat and stable glucose lowering effect in type 2 diabetes Diabetes Obes Metab 14 944-950

[8] Bhargava A(2002)Hypoglycaemia: the limiting factor in the glycaemic management of type 1 and type 2 diabetes Diabetologia 45 937-15

[9] Jain R(2007)A critical review of the literature on fear of hypoglycemia in diabetes: implications for diabetes management and patient education Patient Educ Couns 68 10-292

[10] Mersebach H(2014)Reduced risk of hypoglycemia with insulin degludec versus insulin glargine in patients with type 2 diabetes requiring high doses of basal insulin: a meta-analysis of 5 randomized begin trials Endocr Pract 20 285-18S

[1] Garber AJ(2012)Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN basal-bolus type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial Lancet 21 1498-1507

[2] King AB(2012)Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long) Diabetes Care 35 2464-2471

[3] Del Prato S(2013)Low volume insulin degludec 200U/ml once-daily improves glycemic control similar to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN™ LOW VOLUME trial Diabetes Care 36 2536-2542

[4] Zinman B(2013)The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel group, treat-to-target trial in individuals with type 2 diabetes Diabetes Care 36 858-864

[5] Philis-Tsimikas A(2013)Insulin degludec compared with insulin glargine in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, Pan-Asian, treat-to-target trial J Diabetes Investig 4 605-612

[6] Cariou B(2014)Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes Diabetes Obes Metab 14 859-864

[7] Gough S(2012)Ultra-long acting insulin degludec has a flat and stable glucose lowering effect in type 2 diabetes Diabetes Obes Metab 14 944-950

[8] Bhargava A(2002)Hypoglycaemia: the limiting factor in the glycaemic management of type 1 and type 2 diabetes Diabetologia 45 937-15

[9] Jain R(2007)A critical review of the literature on fear of hypoglycemia in diabetes: implications for diabetes management and patient education Patient Educ Couns 68 10-292

[10] Mersebach H(2014)Reduced risk of hypoglycemia with insulin degludec versus insulin glargine in patients with type 2 diabetes requiring high doses of basal insulin: a meta-analysis of 5 randomized begin trials Endocr Pract 20 285-18S